当前位置: 首页 > 期刊 > 《中国医药导报》 > 2019年第15期
编号:1356750
新型APJ配体-肽类激素Elabela在心血管系统中的研究进展
http://www.100md.com 2019年7月18日 中国医药导报 2019年第15期
     黄思慧 唐其柱

    [摘要] Elabela是一种新型的内源性血管紧张素受体AT1相关受体蛋白(APJ)配体,早期研究认为其主要表达于胚胎组织中,但近年来的研究发现作为一种内源性激素,Elabela在胚胎发育之后同样表达于心脏血管等组织器官中。APJ在哺乳动物心血管系统中发挥调控作用,而作为APJ配体之一的Elabela同样在心血管系统中有着重要作用。本文主要探讨Elabela在心血管发育及心血管疾病中的作用及其临床应用前景。

    [关键词] Elabela;APJ配体;心血管系统;心血管疾病

    [中图分类号] R54 ? ? ? ? ?[文献标识码] A ? ? ? ? ?[文章编号] 1673-7210(2019)05(c)-0025-04

    [Abstract] Elabela is a new type of endogenous angiotensin receptor AT1-related receptor protein (APJ) ligand, which was believed to be mainly expressed in embryonic tissues in early studies, but recent studies have found that as an endogenous hormone, Elabela is also expressed in tissues and organs such as heart and blood vessels after embryonic development. APJ plays a regulatory role in the cardiovascular system of mammals, and Elabela, as one of the APJ ligands, also plays an important role in the cardiovascular system. This paper mainly discusses the role of Elabela in cardiovascular development and cardiovascular diseases and its clinical application prospect.

    [Key words] Elabela; APJ ligand; Cardiovascular system; Cardiovascular disease ......

您现在查看是摘要页,全文长 14817 字符